{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:13:58Z","timestamp":1792620838712,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Science Research Innovation Team Project of Anhui Colleges and Universities","award":["2016-40"],"award-info":[{"award-number":["2016-40"]}]},{"name":"Bengbu City Natural Science Foundation","award":["2019-12"],"award-info":[{"award-number":["2019-12"]}]},{"name":"Key Projects of Science Research of Bengbu Medical College","award":["BYKY2019009ZD"],"award-info":[{"award-number":["BYKY2019009ZD"]}]},{"name":"National University Students\u2019 Innovation and Entrepreneurship Training Program","award":["201910367001"],"award-info":[{"award-number":["201910367001"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.phrs.2020.105207","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T13:21:12Z","timestamp":1600694472000},"page":"105207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":118,"special_numbering":"C","title":["Ivermectin, a potential anticancer drug derived from an antiparasitic drug"],"prefix":"10.1016","volume":"163","author":[{"given":"Mingyang","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4613","key":"10.1016\/j.phrs.2020.105207_bib0005","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.6308762","article-title":"Ivermectin: a potent new antiparasitic agent","volume":"221","author":"Campbell","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.phrs.2020.105207_bib0010","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpddr.2019.06.002","article-title":"Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance","volume":"10","author":"Prichard","year":"2019","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"2","key":"10.1016\/j.phrs.2020.105207_bib0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijantimicag.2019.05.003","article-title":"Ivermectin: From theory to clinical application","volume":"54","author":"Ashour","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0304-4017(93)90218-C","article-title":"Doramectin--a potent novel endectocide","volume":"49","author":"Goudie","year":"1993","journal-title":"Vet Parasitol"},{"issue":"3-4","key":"10.1016\/j.phrs.2020.105207_bib0025","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0304-4017(00)00289-2","article-title":"Selamectin: a novel broad-spectrum endectocide for dogs and cats","volume":"91","author":"Bishop","year":"2000","journal-title":"Vet Parasitol"},{"issue":"6","key":"10.1016\/j.phrs.2020.105207_bib0030","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.pt.2017.02.004","article-title":"Ivermectin - Old Drug, New Tricks?","volume":"33","author":"Laing","year":"2017","journal-title":"Trends Parasitol"},{"issue":"5","key":"10.1016\/j.phrs.2020.105207_bib0035","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ja.2017.11","article-title":"Ivermectin: enigmatic multifaceted\u2019 wonder\u2019 drug continues to surprise and exceed expectations","volume":"70","author":"Crump","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"issue":"12","key":"10.1016\/j.phrs.2020.105207_bib0040","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1039\/C5NP90043C","article-title":"Recognition of the role of Natural Products as drugs to treat neglected tropical diseases by the 2015 Nobel prize in physiology or medicine","volume":"32","author":"McKerrow","year":"2015","journal-title":"Nat Prod Rep"},{"issue":"25","key":"10.1016\/j.phrs.2020.105207_bib0045","doi-asserted-by":"crossref","first-page":"13949","DOI":"10.1073\/pnas.240464697","article-title":"Drug-resistant Drosophila indicate glutamate-gated chloride channels are targets for the antiparasitics nodulisporic acid and ivermectin","volume":"97","author":"Kane","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.phrs.2020.105207_bib0050","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1073\/pnas.76.4.2062","article-title":"Avermectin B1a irreversibly blocks postsynaptic potentials at the lobster neuromuscular junction by reducing muscle membrane resistance","volume":"76","author":"Fritz","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.phrs.2020.105207_bib0055","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(18)30163-4","article-title":"Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial","volume":"18","author":"Smit","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"10180","key":"10.1016\/j.phrs.2020.105207_bib0060","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(18)32321-3","article-title":"Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial","volume":"393","author":"Foy","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.phrs.2020.105207_bib0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4103\/0972-9062.213454","article-title":"Effect of ivermectin on Trypanosoma brucei brucei in experimentally infected mice","volume":"49","author":"Udensi","year":"2012","journal-title":"J Vector Borne Dis"},{"issue":"5","key":"10.1016\/j.phrs.2020.105207_bib0070","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/ja.2017.31","article-title":"Ivermectin efficacy against Biomphalaria, intermediate host snail vectors of Schistosomiasis","volume":"70","author":"Katz","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"issue":"3","key":"10.1016\/j.phrs.2020.105207_bib0075","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3347\/kjp.2013.51.3.297","article-title":"Therapeutic potential of myrrh and ivermectin against experimental Trichinella spiralis infection in mice","volume":"51","author":"B. MM","year":"2013","journal-title":"The Korean journal of parasitology"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/vbz.2009.0030","article-title":"Effects of ivermectin on blood-feeding Phlebotomus papatasi, and the promastigote stage of Leishmania major","volume":"11","author":"Hanafi","year":"2011","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"8","key":"10.1016\/j.phrs.2020.105207_bib0085","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/jac\/dks147","article-title":"Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug","volume":"67","author":"Mastrangelo","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.phrs.2020.105207_bib0090","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin is a specific inhibitor of importin alpha\/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus","volume":"443","author":"Wagstaff","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.phrs.2020.105207_bib0095","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"issue":"6","key":"10.1016\/j.phrs.2020.105207_bib0100","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00011-011-0307-8","article-title":"Anti-inflammatory effects of ivermectin in mouse model of allergic asthma","volume":"60","author":"Yan","year":"2011","journal-title":"Inflamm Res"},{"key":"10.1016\/j.phrs.2020.105207_bib0105","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fnins.2014.00176","article-title":"P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and\/or treat alcohol use disorders","volume":"8","author":"Franklin","year":"2014","journal-title":"Front Neurosci"},{"issue":"7","key":"10.1016\/j.phrs.2020.105207_bib0110","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/00001813-199609000-00005","article-title":"The abamectin derivative ivermectin is a potent p-glycoprotein inhibitor","volume":"7","author":"Didier","year":"1996","journal-title":"Anticancer Drugs."},{"issue":"13","key":"10.1016\/j.phrs.2020.105207_bib0115","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.bmcl.2019.04.045","article-title":"Doxycycline, salinomycin, monensin and ivermectin repositioned as cancer drugs","volume":"29","author":"Markowska","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"2","key":"10.1016\/j.phrs.2020.105207_bib0120","first-page":"317","article-title":"The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug","volume":"8","author":"Juarez","year":"2018","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.phrs.2020.105207_bib0125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/DDDT.S237393","article-title":"Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin","volume":"14","author":"Liu","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.phrs.2020.105207_bib0130","doi-asserted-by":"crossref","first-page":"172784","DOI":"10.1016\/j.ejphar.2019.172784","article-title":"Old wine in new bottles: Drug repurposing in oncology","volume":"866","author":"Antoszczak","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0135","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.3802\/jgo.2019.30.e10","article-title":"Current state and outlook for drug repositioning anticipated in the field of ovarian cancer","volume":"30","author":"Kobayashi","year":"2019","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-017-0436-9","article-title":"Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment","volume":"10","author":"Yoshida","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0145","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drudis.2015.09.017","article-title":"Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds","volume":"21","author":"Wurth","year":"2016","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0150","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"10071","key":"10.1016\/j.phrs.2020.105207_bib0155","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0140-6736(16)31392-7","article-title":"The global burden of women\u2019s cancers: a grand challenge in global health","volume":"389","author":"Ginsburg","year":"2017","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.phrs.2020.105207_bib0160","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1158\/0008-5472.CAN-15-2887","article-title":"Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1\/Akt Axis in Breast Cancer","volume":"76","author":"Dou","year":"2016","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0165","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12917-019-2026-2","article-title":"Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling","volume":"15","author":"Diao","year":"2019","journal-title":"BMC Vet Res"},{"issue":"4","key":"10.1016\/j.phrs.2020.105207_bib0170","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040819","article-title":"Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes","volume":"12","author":"Diana","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2020.105207_bib0175","doi-asserted-by":"crossref","first-page":"104683","DOI":"10.1016\/j.phrs.2020.104683","article-title":"Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer","volume":"153","author":"Deepak","year":"2020","journal-title":"Pharmacol Res"},{"issue":"8","key":"10.1016\/j.phrs.2020.105207_bib0180","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1158\/1535-7163.MCT-14-0980-T","article-title":"Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer","volume":"14","author":"Kwon","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.phrs.2020.105207_bib0185","doi-asserted-by":"crossref","first-page":"16222","DOI":"10.1038\/srep16222","article-title":"Modulation of P2X4\/P2X7\/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death","volume":"5","author":"Draganov","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.phrs.2020.105207_bib0190","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030695","article-title":"Emerging Role of Circulating Tumor Cells in Gastric Cancer","volume":"12","author":"Thanh Huong","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"64","key":"10.1016\/j.phrs.2020.105207_bib0195","doi-asserted-by":"crossref","first-page":"107666","DOI":"10.18632\/oncotarget.22587","article-title":"Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer","volume":"8","author":"Nambara","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.phrs.2020.105207_bib0200","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41568-019-0168-y","article-title":"YAP and TAZ: a signalling hub of the tumour microenvironment","volume":"19","author":"Zanconato","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.phrs.2020.105207_bib0205","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.15252\/emmm.201404084","article-title":"The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer","volume":"6","author":"Melotti","year":"2014","journal-title":"EMBO Mol Med"},{"issue":"10","key":"10.1016\/j.phrs.2020.105207_bib0210","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0215","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1073\/pnas.1517188113","article-title":"Dysregulated YAP1\/TAZ and TGF-beta signaling mediate hepatocarcinogenesis in Mob1a\/1b-deficient mice","volume":"113","author":"Nishio","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.phrs.2020.105207_bib0220","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.21873\/anticanres.13669","article-title":"Anti-parasitic Drug Ivermectin Exhibits Potent Anticancer Activity Against Gemcitabine-resistant Cholangiocarcinoma In Vitro","volume":"39","author":"Intuyod","year":"2019","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0225","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s13046-019-1347-0","article-title":"The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1\/G3BP1-SPP1- NF-kappaB signaling axis","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0230","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12967-019-2113-y","article-title":"Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma","volume":"17","author":"Xu","year":"2019","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0235","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.phrs.2020.105207_bib0240","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbrc.2017.08.097","article-title":"Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage","volume":"492","author":"Zhu","year":"2017","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"6","key":"10.1016\/j.phrs.2020.105207_bib0245","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4329\/wjr.v4.i6.241","article-title":"Epidemiology of prostate cancer and treatment remarks","volume":"4","author":"Arcangeli","year":"2012","journal-title":"World J Radiol"},{"issue":"2","key":"10.1016\/j.phrs.2020.105207_bib0250","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1172\/JCI130819","article-title":"Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models","volume":"130","author":"Nappi","year":"2020","journal-title":"J Clin Invest"},{"issue":"18","key":"10.1016\/j.phrs.2020.105207_bib0255","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1182\/blood-2010-01-262675","article-title":"The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells","volume":"116","author":"Sharmeen","year":"2010","journal-title":"Blood"},{"issue":"9976","key":"10.1016\/j.phrs.2020.105207_bib0260","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0265","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bbrc.2018.02.063","article-title":"Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress","volume":"497","author":"Wang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0270","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1080\/21691401.2019.1664560","article-title":"Downregulation of miR-146a promotes tumorigenesis of cervical cancer stem cells via VEGF\/CDC42\/PAK1 signaling pathway","volume":"47","author":"Dong","year":"2019","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1016\/j.phrs.2020.105207_bib0275","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8909852","article-title":"Relationship between Oxidative Stress and Physical Activity in Women with Squamous Intraepithelial Lesions in a Cervical Cancer Control Program in the Brazilian Amazon","volume":"2019","author":"Carneiro","year":"2019","journal-title":"Oxid Med Cell Longev"},{"issue":"2","key":"10.1016\/j.phrs.2020.105207_bib0280","doi-asserted-by":"crossref","first-page":"e12543","DOI":"10.1111\/cpr.12543","article-title":"Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway","volume":"52","author":"Zhang","year":"2019","journal-title":"Cell Prolif"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0285","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13148-018-0602-0","article-title":"Epigenetic therapy for ovarian cancer: promise and progress","volume":"11","author":"Moufarrij","year":"2019","journal-title":"Clin Epigenetics"},{"issue":"6","key":"10.1016\/j.phrs.2020.105207_bib0290","first-page":"243","article-title":"Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines","volume":"3","author":"Hashimoto","year":"2009","journal-title":"Drug Discov Ther"},{"issue":"35","key":"10.1016\/j.phrs.2020.105207_bib0295","doi-asserted-by":"crossref","first-page":"E7301","DOI":"10.1073\/pnas.1705441114","article-title":"In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer","volume":"114","author":"Kodama","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.phrs.2020.105207_bib0300","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.amjms.2019.11.001","article-title":"Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt\/mTOR Signaling","volume":"359","author":"Zhang","year":"2020","journal-title":"Am J Med Sci"},{"issue":"7","key":"10.1016\/j.phrs.2020.105207_bib0305","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41582-019-0220-2","article-title":"Genetic and molecular epidemiology of adult diffuse glioma","volume":"15","author":"Molinaro","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"10.1016\/j.phrs.2020.105207_bib0310","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMra0708126","article-title":"Malignant gliomas in adults","volume":"359","author":"Wen","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.phrs.2020.105207_bib0315","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.bbrc.2016.10.064","article-title":"Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress","volume":"480","author":"Liu","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"10.1016\/j.phrs.2020.105207_bib0320","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20192489","article-title":"Ivermectin induces autophagy-mediated cell death through the AKT\/mTOR signaling pathway in glioma cells","volume":"39","author":"Liu","year":"2019","journal-title":"Biosci Rep"},{"issue":"21","key":"10.1016\/j.phrs.2020.105207_bib0325","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1038\/onc.2010.620","article-title":"Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas","volume":"30","author":"Kwak","year":"2011","journal-title":"Oncogene"},{"issue":"Pt 9","key":"10.1016\/j.phrs.2020.105207_bib0330","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/brain\/awv167","article-title":"DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating miR-21 biogenesis","volume":"138","author":"Yin","year":"2015","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.phrs.2020.105207_bib0335","first-page":"325","article-title":"Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications","volume":"15","author":"Kircik","year":"2016","journal-title":"J Drugs Dermatol"},{"issue":"10192","key":"10.1016\/j.phrs.2020.105207_bib0340","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2020.105207_bib0345","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.2147\/DDDT.S172538","article-title":"Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth","volume":"12","author":"Gallardo","year":"2018","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1016\/j.phrs.2020.105207_bib0350","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2017.10.015","article-title":"Radiomics and radiogenomics in lung cancer: A review for the clinician","volume":"115","author":"Thawani","year":"2018","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2020.105207_bib0355","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020482","article-title":"Current Advances in the Treatment of BRAF-Mutant Melanoma","volume":"12","author":"Patel","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2020.105207_bib0360","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2019.08.032","article-title":"A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma","volume":"123","author":"Franken","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0365","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clsc.2016.05.001","article-title":"Macrocyclic Lactones Block Melanoma Growth, Metastases Development and Potentiate Activity of Anti\u2013 BRAF V600 Inhibitors","volume":"1","author":"Gallardo","year":"2016","journal-title":"Clinical Skin Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2020.105207_bib0370","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/jcb.27490","article-title":"Suppressing ROS\u2010TFE3\u2010dependent autophagy enhances ivermectin\u2010induced apoptosis in human melanoma cells","volume":"120","author":"Deng","year":"2018","journal-title":"Journal of Cellular Biochemistry"},{"key":"10.1016\/j.phrs.2020.105207_bib0375","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-immunol-042617-053010","article-title":"Apoptosis and Clearance of Apoptotic Cells","volume":"36","author":"Nagata","year":"2018","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"10.1016\/j.phrs.2020.105207_bib0380","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrm2393","article-title":"Expansion and evolution of cell death programmes","volume":"9","author":"Degterev","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"10.1016\/j.phrs.2020.105207_bib0385","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.cell.2019.05.026","article-title":"Autophagy-Independent Functions of the Autophagy Machinery","volume":"177","author":"Galluzzi","year":"2019","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.phrs.2020.105207_bib0390","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrc.2017.53","article-title":"Targeting autophagy in cancer","volume":"17","author":"Levy","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2020.105207_bib0395","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1158\/0008-5472.CAN-13-2966","article-title":"The four faces of autophagy: implications for cancer therapy","volume":"74","author":"Gewirtz","year":"2014","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.phrs.2020.105207_bib0400","doi-asserted-by":"crossref","first-page":"856","DOI":"10.15252\/embj.201490784","article-title":"Autophagy in malignant transformation and cancer progression","volume":"34","author":"Galluzzi","year":"2015","journal-title":"Embo j"},{"issue":"4","key":"10.1016\/j.phrs.2020.105207_bib0405","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nrclinonc.2016.183","article-title":"Activating autophagy to potentiate immunogenic chemotherapy and radiation therapy","volume":"14","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.phrs.2020.105207_bib0410","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/15548627.2016.1256522","article-title":"Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis","volume":"13","author":"Ravegnini","year":"2017","journal-title":"Autophagy"},{"issue":"2","key":"10.1016\/j.phrs.2020.105207_bib0415","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrm3735","article-title":"Self-consumption: the interplay of autophagy and apoptosis","volume":"15","author":"Marino","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.phrs.2020.105207_bib0420","doi-asserted-by":"crossref","first-page":"109595","DOI":"10.1016\/j.biopha.2019.109595","article-title":"Pyroptosis: A new frontier in cancer","volume":"121","author":"Fang","year":"2020","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.phrs.2020.105207_bib0425","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","article-title":"DAMP-sensing receptors in sterile inflammation and inflammatory diseases","volume":"20","author":"Gong","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"7610","key":"10.1016\/j.phrs.2020.105207_bib0430","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature18629","article-title":"Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores","volume":"535","author":"Liu","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.phrs.2020.105207_bib0435","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041456","article-title":"Mechanisms and Therapeutic Regulation of Pyroptosis in Inflammatory Diseases and Cancer","volume":"21","author":"Zheng","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.phrs.2020.105207_bib0440","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1096\/fj.201903287R","article-title":"P2X4 receptor exacerbates ischemic AKI and induces renal proximal tubular NLRP3 inflammasome signaling","volume":"34","author":"Han","year":"2020","journal-title":"Faseb j"},{"issue":"12","key":"10.1016\/j.phrs.2020.105207_bib0445","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1158\/1078-0432.CCR-09-2824","article-title":"Cancer stem cells and self-renewal","volume":"16","author":"O\u2019Brien","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"37","key":"10.1016\/j.phrs.2020.105207_bib0450","doi-asserted-by":"crossref","first-page":"39550","DOI":"10.18632\/oncotarget.6098","article-title":"Differentiation and transdifferentiation potentials of cancer stem cells","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"issue":"7120","key":"10.1016\/j.phrs.2020.105207_bib0455","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.phrs.2020.105207_bib0460","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc1590","article-title":"Tumour stem cells and drug resistance","volume":"5","author":"Dean","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.phrs.2020.105207_bib0465","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/jnci\/djn123","article-title":"Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy","volume":"100","author":"Li","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.phrs.2020.105207_bib0470","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/jnci\/djj505","article-title":"Cancer stem cells and radiotherapy: new insights into tumor radioresistance","volume":"98","author":"Diehn","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.phrs.2020.105207_bib0475","first-page":"3397","article-title":"Ivermectin as an inhibitor of cancer stemlike cells","volume":"17","author":"Dominguez-Gomez","year":"2018","journal-title":"Mol Med Rep"},{"issue":"10","key":"10.1016\/j.phrs.2020.105207_bib0480","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101527","article-title":"The PAK1-Stat3 Signaling Pathway Activates IL-6 Gene Transcription and Human Breast Cancer Stem Cell Formation","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"48","key":"10.1016\/j.phrs.2020.105207_bib0485","doi-asserted-by":"crossref","first-page":"84559","DOI":"10.18632\/oncotarget.19187","article-title":"Novel strategies to prevent the development of multidrug resistance (MDR) in cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.phrs.2020.105207_bib0490","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/17425255.2016.1196186","article-title":"Nano-based strategies to overcome p-glycoprotein-mediated drug resistance","volume":"12","author":"Niazi","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.phrs.2020.105207_bib0495","doi-asserted-by":"crossref","first-page":"100681","DOI":"10.1016\/j.drup.2020.100681","article-title":"Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update","volume":"49","author":"Dong","year":"2020","journal-title":"Drug Resist Updat"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0500","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12272-013-0276-2","article-title":"Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system","volume":"37","author":"Kibria","year":"2014","journal-title":"Arch Pharm Res"},{"issue":"3","key":"10.1016\/j.phrs.2020.105207_bib0505","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cbi.2005.11.002","article-title":"Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3)","volume":"159","author":"Lespine","year":"2006","journal-title":"Chem Biol Interact"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0510","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0006-2952(96)00656-9","article-title":"Reversal of P-glycoprotein-associated multidrug resistance by ivermectin","volume":"53","author":"Pouliot","year":"1997","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0515","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ejps.2006.10.004","article-title":"Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship","volume":"30","author":"Lespine","year":"2007","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0520","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-019-1251-7","article-title":"Ivermectin reverses the drug resistance in cancer cells through EGFR\/ERK\/Akt\/NF-kappaB pathway","volume":"38","author":"Jiang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"10087","key":"10.1016\/j.phrs.2020.105207_bib0525","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2020.105207_bib0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.02.006","article-title":"Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies","volume":"65","author":"Lim","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.phrs.2020.105207_bib0535","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081195","article-title":"Targeting Heat Shock Protein 27 in Cancer: A Druggable Target for Cancer Treatment?","volume":"11","author":"Choi","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.phrs.2020.105207_bib0540","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1892","article-title":"p21-activated kinases in cancer","volume":"6","author":"Kumar","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.phrs.2020.105207_bib0545","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.semcancer.2018.01.006","article-title":"P21 activated kinase signaling in cancer","volume":"54","author":"Rane","year":"2019","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"10.1016\/j.phrs.2020.105207_bib0550","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1136\/gutjnl-2014-306768","article-title":"Tracing PAKs from GI inflammation to cancer","volume":"63","author":"Dammann","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105207_bib0555","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/bs.acr.2016.01.002","article-title":"PAKs in Human Cancer Progression: From Inception to Cancer Therapeutic to Future Oncobiology","volume":"130","author":"Kumar","year":"2016","journal-title":"Adv Cancer Res"},{"issue":"10","key":"10.1016\/j.phrs.2020.105207_bib0560","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/009127002237994","article-title":"Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects","volume":"42","author":"Guzzo","year":"2002","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.phrs.2020.105207_bib0565","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2885.2008.01007.x","article-title":"Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice","volume":"32","author":"Geyer","year":"2009","journal-title":"J Vet Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.phrs.2020.105207_bib0570","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1211\/jpp.62.03.0016","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance in vitro by doramectin and nemadectin","volume":"62","author":"Gao","year":"2010","journal-title":"J Pharm Pharmacol"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820315152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820315152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:23:37Z","timestamp":1760912617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820315152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":114,"alternative-id":["S1043661820315152"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105207","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ivermectin, a potential anticancer drug derived from an antiparasitic drug","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105207","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105207"}}